Please login to the form below

Not currently logged in
Email:
Password:

Former NICE chair Sir Michael Rawlins to lead MHRA

He will take up his new role at the UK's medicines and devices regulator in December

sir-michael-rawlins-mhraThe UK's Medicines and Healthcare Products Regulatory Agency (MHRA) has named UK healthcare veteran Sir Michael Rawlins as its new chair.

Sir Michael will take up his new post on December 1, 2014 and replace Sir Gordon Duff, who earlier this year announced his intention to step down from the regulator to focus on his academic career.

Sir Gordon has been in the position for just under two years during which time he has overseen a period of major change for the agency, which is responsible for protecting and improving the health of people in the UK

The task will now fall to Sir Michael, who is no stranger to senior positions in UK healthcare having spent 14 years as chairman of the National Institute for Health and Care Excellence (NICE) from its formation in 1999 to his departure last year.

He is also an honorary professor at the London School of Hygiene and Tropical Medicine, University of London, and emeritus professor at the University of Newcastle upon Tyne.

More recently Sir Michael has served on the board of US-based biotech Intra-Cellular Therapeutics.

The appointment was welcomed by England's chief medical officer Prof Dame Sally Davies.

“I am delighted at Sir Michael Rawlins' appointment as agency chair,” she said. “He will bring a wealth of experience to the Board and will play a key role in the leadership of our national regulator who will continue to focus on excellence and innovation.”

4th November 2014

From: Regulatory

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
W2O Group

W2O Group is an integrated marketing agency with expertise in brand and digital strategy, creative development and communications services. We...

Latest intelligence

US biosimilars
The US celebrates five years of biosimilars on the market – a look to the past, present and future
Why the success of biosimilars in the US has been mixed...
Harness the power of data to map new patient pathways
Oli Hudson, of Wilmington Healthcare, explains why pharma needs to put data at the heart of its bid to support the NHS Reset...
What NORD’s RareInsights® 30-year comparative analysis means to us and our clients at OPEN Health
...

Infographics